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Supplemental Table 1. Association of pre-diagnostic reproductive factors and survival among EOC overall 
when stratifying by histologic subtypea,b,c 
    Non-serous       Serous       
 Total Fatal Cases HR 95% CI Total Fatal Cases HR 95% CI Pint 
  n n (%)     n n (%)       
Age at menarched, y        
<12 43 13 (30.2%) REF  84 48 (57.1%) REF   
12 53 15 (28.3%) 0.78 0.33-1.83 102 50 (49.0%) 1.10 0.71-1.69  
13 59 17 (28.8%) 0.51  0.21-1.23 145 76 (52.4%) 0.82 0.55-1.23  
14 45 13 (28.9%) 0.30 0.12-0.77 134 67 (50.0%) 0.79 0.52-1.20  
14+ 45 20 (44.4%) 0.65 0.27-1.57 98 54 (55.1%) 0.92  0.59-1.44 0.27 
Ptrend   0.35    0.69   
Parousd          
No 49 17 (34.7%) REF  86 49 (57.0%) REF   
Yes 189 59 (31.2%) 0.42 0.27-1.57 474 245 (51.7%) 0.96 0.69-1.33 0.06 
Number of FTPsd,e          
1 25 4 (16.0%) REF  101 48 (47.5%) REF   
2 98 37 (37.8%) 2.46 0.76-7.93 215 109 (50.7%) 0.95  0.64-1.39  
3+ 61 18 (29.5%) 2.24 0.59-8.55 148 82 (55.4%) 1.10 0.73-1.65 0.15 
Ptrend   0.07    0.38   
Age at first FTPd,e, y        
<=20 21 10 (47.6%) REF  61 31 (50.8%) REF   
>20-<=25 96 28 (29.2%) 0.41  0.14-1.20 208 94 (45.2%) 0.59 0.38-0.92  
>25-<=30 54 15 (27.8%) 0.47 0.14-1.54 145 83 (57.2%) 0.75 0.47-1.20  
>30 17 6 (35.3%) 1.22 0.28-5.35 56 35 (62.5%) 0.71 0.40-1.23 0.63 
Ptrend   0.62    0.75   
Breastfeedinge,f          
Never 25 8 (32.0%) REF  69 34 (49.3%) REF   
Ever 148 48 (32.4%) 0.31 0.09-1.03 376 192 (51.1%) 0.92 0.61-1.38 0.54 
Duration of breastfeedingd,g, m        
<=3 32 12 (37.5%) REF  130 65 (50.0%) REF   
>3-<=6 26 5 (19.2%) 0.54  0.14-2.09 75 39 (52.0%) 1.07 0.68-1.69  
>6-<=12 44 18 (40.9%) 1.66 0.54-5.09 75 33 (44.0%) 0.60 0.37-0.99  
>12-<=24 35 10 (28.6%) 0.74  0.23-2.36 69 38 (55.1%) 0.90 0.56-1.43  
>24 9 3 (33.3%) 0.98 0.12-7.72 27 17 (63.0%) 1.13 0.61-2.08 0.18 
Ptrend   0.69    0.48   
OC used          
Never 111 35 (31.5%) REF  275 148 (53.8%) REF   
Ever 137 43 (31.4%) 1.00 0.56-1.78 289 147 (50.9%) 0.95  0.73-1.23 0.20 
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    Non-serous       Serous       
 Total Fatal Cases HR 95% CI Total Fatal Cases HR 95% CI Pint 
  n n (%)     n n (%)       
Duration of OC useh,i, y         
<=1 31 6 (19.4%) REF  67 30 (44.8%) REF   
>1-<=5 46 7 (15.2%) 0.28  0.05-1.63 94 50 (53.2%) 1.05 0.61-1.78  
>5-<=10 26 12 (46.2%) 0.94 0.21-4.12 58 26 (44.8%) 1.15 0.63-2.12  
>10 19 13 (68.4%) 4.12  0.70-24.19 46 28 (60.9%) 1.31 0.71-2.40 0.01 
Ptrend   0.003    0.42   
Age at menopausej,k, y         
<=45 14 4 (28.6%) 1.84 0.35-9.63 52 33 (63.5%) 1.38 0.83-2.30  
46-50 47 19 (40.4%) REF  112 65 (58.0%) REF   
51-52 20 8 (40.0%) 3.58 0.89-14.36 55 29 (52.7%) 0.97 0.58-1.61  
>52 34 11 (32.4%) 1.66 0.50-5.55 68 45 (66.2%) 1.11 0.71-1.75 0.80 
Ptrend   0.99    0.64   
MHT used,j,l          
Never 59 17 (28.8%) REF  151 94 (62.3%) REF   
Ever 45 23 (51.1%) 3.97 1.25-12.58 144 80 (55.6%) 0.63 0.44-0.90 0.003 
MHT timing of use at baselined,j,l        
Former use 16 7 (43.8%) 3.27  0.79-13.49 42 25 (59.5%) 0.73 0.45-1.18  
Current use 27 16 (59.3%) 5.07 1.41-18.29 101 54 (53.5%) 0.60 0.39-0.90 0.002 
MHT duration of use at baselinej,l,m, y        
use <5 years 21 10 (47.6%) 7.49 1.43-39.15 78 43 (55.1%) 0.79 0.51-1.21  
use >=5 years 17 10 (58.8%) 5.57 1.20-25.97 52 29 (55.8%) 0.55 0.35-0.87 0.01 
Ptrend   0.21    0.01   
MHT formulation at baseline (current users only)j,l,n       
E only 7 3 (42.9%) N/A  21 16 (76.2%) 0.64 0.34-1.18  
E+P 17 11 (64.7%) 8.28 1.03-66.41 65 32 (49.2%) 0.61 0.36-1.02  
Other 1 1 (100.0%) N/A  7 3 (42.9%) 0.35 0.08-1.50 N/A 
Hysterectomyo          
No 191 61 (31.9%) REF  452 231 (51.1%) REF   
Yes 16 4 (25.0%) 0.60 0.16-2.21 58 31 (53.4%) 0.80 0.53-1.21 0.85 
Total ovulatory yearsp         
Q1 57 21 (36.8%) REF  119 57 (47.9%) REF   
Q2 55 16 (29.1%) 0.71 0.32-1.57 117 65 (55.6%) 1.33 0.87-2.04  
Q3 42 13 (31.0%) 0.46 0.20-1.06 124 55 (44.4%) 0.73 0.47-1.13  
Q4 46 12 (26.1%) 0.71 0.27-1.88 101 61 (60.4%) 1.22 0.79-1.88 0.10 
Ptrend     0.02       0.72     
Abbreviations: CI=confidence interval; FTP=full term pregnancy; HR=hazard ratio; MHT=menopausal 
hormone therapy; m=months; OC=oral contraceptive; y=years. 
aAll models were adjusted for age at diagnosis (continuous), year of diagnosis (continuous), BMI 
(<23kg/m2, ≥23-<25 [reference], ≥25 -<30, ≥30), tumour stage (local [reference], regional, metastatic and 
unknown), smoking status (never [reference], former, current and unknown) and stratified by study centre  
bTotal number of cases; non-serous (total n=249) comprised of 74 mucinous, 126 endometrioid, and 49 clear 
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cell; serous (n= 568)  cTotal number of fatal cases; non-serous (total n=79) comprised of 27 mucinous, 39 
endometrioid, and 13 clear cell; serous (n= 298)  dMissing for <5% of the cohort (based on all EOC cases)  
eAmong parous women only  fBreastfeeding was missing for 6.4% of the cohort (based on all EOC cases)  
gAmong parous women who had ever breastfed  hAmong OC users only  iDuration of OC use was missing 
for 8.3% of women reporting use of OCs (based on all EOC cases)  jAmong postmenopausal women only  
kAge at menopause was missing for 18.6% of postmenopausal women (based on all EOC cases)  
lParticipants from Greece and Sweden were excluded from this analysis as detailed data on MHT use were 
unavailable  mMHT duration was missing for 11.2% of individuals who ever used MHT  nMHT formulation 
was missing for 6.9% of the individuals who reported current use  oHysterectomy was missing for 10.3% of 




Supplemental Table 2. Association between pre-diagnostic reproductive factors and survival among EOC 
overall, restricted to cases with FIGO stage II/III tumors 
Totala Fatal Casesb Model 1  95% CI Model 2 95% CI 
 n n (%) HRc  HRd  
Age at menarchee, y 
<12 57 30 (52.6) REF REF 
12 68 35 (51.5) 1.00 0.59-1.70 1.04 0.61-1.79 
13 76 41 (53.9) 1.05 0.63-1.74 1.04 0.62-1.74 
14 104 55 (52.9) 1.05 0.64-1.71 1.07 0.65-1.77 
>14 70 41 (58.6) 1.14 0.68-1.92 1.11 0.65-1.89 
ptrend 0.57 0.65 
Parouse 
No 59 33 (55.9) REF REF 
Yes 306 165 (53.9) 0.94 0.64-1.40 0.93 0.62-1.38 
Number of FTPse,f 
1 60 29 (48.3) REF REF 
2 153 75 (49.0) 1.13 0.71-1.80 1.14 0.71-1.84 
3+ 85 55 (64.7) 1.54 0.93-2.54 1.57 0.93-2.66 
ptrend 0.02 0.02 
Age at first FTPf, y 
≤20 29 19 (65.5) REF REF 
>20-≤25 147 68 (46.3) 0.41 0.23-0.71 0.36 0.20-0.65 
>25-≤30 94 58 (61.7) 0.65 0.37-1.16 0.62 0.34-1.13 
>30 36 20 (55.6) 0.46 0.23-0.91 0.41 0.20-0.82 
ptrend 0.97 0.97 
Breastfeedingf,g 
Never 49 24 (49.0) REF REF 
Ever 235 125 (53.2) 0.96 0.59-1.56 0.94 0.58-1.53 
Duration of breastfeedingh, m 
≤3 90 49 (54.4) REF REF 
>3-≤6 45 21 (46.7) 0.92 0.52-1.62 0.85 0.47-1.55 
>6-≤12 57 26 (45.6) 0.67 0.40-1.13 0.65 0.37-1.15 
>12-≤24 33 21 (63.6) 1.21 0.67-2.16 1.23 0.67-2.25 
>24 10 8 (80.0) 2.40 0.92-6.25 2.52 0.92-6.93 
ptrend 0.32 0.24 
OC usee 
Never 183 104 (56.8) REF REF 
Ever 194 98 (50.5) 0.99 0.72-1.35 1.01 0.73-1.39 
Duration of OC usei,j, y 
≤1 40 18 (45.0) REF REF 
>1-≤5 52 27 (51.9) 1.12 0.55-2.26 1.02 0.46-2.24 
>5-≤10 43 18 (41.9) 1.11 0.52-2.36 1.17 0.53-2.59 
>10 35 23 (65.7) 1.73 0.87-3.45 1.41 0.68-2.91 




Totala Fatal Casesb Model 1  95% CI Model 2 95% CI 
 n n (%) HRc  HRd  
Age at menopausek,l, y 
≤45 29 20 (69.0) 1.95 1.03-3.70 2.05 1.04-4.01 
>45-≤50 74 40 (54.1) REF REF 
>50-≤52 35 20 (57.1) 1.16 0.63-2.13 1.16 0.62-2.17 
>52 55 33 (60.0) 1.09 0.64-1.85 1.07 0.62-1.84 
ptrend 0.25 0.17 
MHT usee,k,m 
Never 96 62 (64.6) REF REF 
Ever 84 45 (53.6) 0.72 0.46-1.13 0.67 0.41-1.08 
MHT timing of use at baselinee,k,m 
Former 26 15 (57.7) 0.60 0.31-1.14 0.53 0.27-1.05 
Current 57 29 (50.9) 0.83 0.49-1.40 0.79 0.45-1.39 
MHT duration of use at baselinek,m,n,y 
<5  44 23 (52.3) 0.71 0.42-1.21 0.71 0.40-1.25 
≥5 29 16 (55.2) 0.77 0.41-1.44 0.70 0.35-1.39 
ptrend 0.58 0.45 
MHT formulation at baseline (current users only)k,m,o 
E only 13 11 (84.6) 1.52 0.70-3.28 1.44 0.63-3.34 
E+P 36 15 (41.7) 0.80 0.40-1.59 0.76 0.36-1.63 
Other 2 1 (50.0) 1.33 0.13-13.34 1.09 0.11-11.15 
Hysterectomyp 
No 280 149 (53.2) REF REF 
Yes 31 16 (51.6) 0.88 0.50-1.53 0.84 0.47-1.49 
Total ovulatory yearsq 
≤27.5 91 51 (56.0) REF REF 
>27.5-≤33.0 60 33 (55.0) 0.73 0.45-1.18 0.78 0.46-1.33 
>33.0-≤36.5 77 35 (45.5) 0.52 0.32-0.86 0.48 0.29-0.80 
>36.5 75 41 (54.7) 0.69 0.42-1.14 0.67 0.40-1.14 
ptrend 0.03 0.02 
Abbreviations: CI=confidence interval; FTP=full term pregnancy; HR=hazard ratio; MHT=menopausal 
hormone therapy; m=months; OC=oral contraceptive; y years. 
aTotal number of cases n=378  bTotal number of fatal cases n=203  cAdjusted for age at diagnosis 
(continuous) and stratified by study centre  dAdjusted for age at diagnosis (continuous), year of diagnosis 
(continuous), BMI (<23kg/m2, ≥23-<25 [reference], ≥25 -<30, ≥30), smoking status (never [reference], 
former, current and unknown) and stratified by study centre  eMissing for ≤3.4% of the cohort  fAmong 
parous women only  gBreastfeeding was missing for 7.2% of the cohort  hAmong parous women who had 
ever breastfed  iAmong OC users only  jDuration of OC use was missing for 12.4% of women  kAmong 
postmenopausal women only  lAge at menopause was missing for 17.5% of women  mParticipants from 
Greece and Sweden were excluded from this analysis as detailed data on MHT use were unavailable  nMHT 
duration was missing for 13.1% of individuals who had ever used MHT  oMHT formulation was missing for 
10.5% of current MHT users  pHysterectomy was missing for 17.7% of the cohort  qTotal ovulatory years 
was missing for 19.8% of the cohort.
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Supplemental Table 3. Association between pre-diagnostic reproductive factors and survival among EOC 
overall, restricted to postmenopausal women at recruitment 
  Totala Fatal Casesb Model 1c Model 2d 
  n n (%) HR (95% CI) HR (95% CI) 
Age at menarchee, y     
<12 85 56 (65.9%) REF REF 
12 107 57 (53.3%) 0.77 (0.52-1.13) 0.92 (0.62-1.37) 
13 145 85 (58.6%) 0.83 (0.58-1.19) 0.76 (0.53-1.10) 
14 152 84 (55.3%) 0.74 (0.52-1.07) 0.68 (0.47-0.98) 
14+ 141 76 (53.9%) 0.74 (0.51-1.07) 0.76 (0.52-1.12) 
Ptrend   0.26 0.16 
Parouse     
No 97 57 (58.8%) REF REF 
Yes 537 304 (56.6%) 1.00 (0.74-1.33) 0.94 (0.70-1.26) 
Number of FTPse,f     
1 99 54 (54.5%) REF REF 
2 237 131 (55.3%) 1.03 (0.74-1.44) 1.01 (0.71-1.43) 
3+ 191 114 (59.7%) 1.12 (0.80-1.57) 1.08 (0.75-1.54) 
Ptrend   0.14 0.29 
Age at first FTPe,f, y     
<=20 71 43 (60.6%) REF REF 
>20-<=25 230 116 (50.4%) 0.62 (0.43-0.90) 0.62 (0.42-0.91) 
>25-<=30 166 98 (59.0%) 0.72 (0.49-1.05) 0.67 (0.45-1.01) 
>30 64 43 (67.2%) 0.93 (0.60-1.46) 0.84 (0.52-1.36) 
Ptrend   0.73 0.83 
Breastfeedingf,g     
Never 81 41 (50.6%) REF REF 
Ever 417 241 (57.8%) 0.87 (0.61-1.24) 0.90 (0.62-1.30) 
Duration of breastfeedinge,h, m    
<=3 126 76 (60.3%) REF REF 
>3-<=6 69 35 (50.7%) 0.68 (0.45-1.05) 0.76 (0.49-1.19) 
>6-<=12 106 56 (52.8%) 0.69 (0.48-1.00) 0.74 (0.50-1.10) 
>12-<=24 81 51 (63.0%) 0.93 (0.64-1.36) 0.92 (0.61-1.37) 
>24 33 23 (69.7%) 1.28 (0.76-2.16) 1.21 (0.71-2.09) 
Ptrend   0.29 0.42 
OC usee     
Never 383 215 (56.1%) REF REF 
Ever 256 147 (57.4%) 1.09 (0.86-1.38) 1.00 (0.78-1.28) 
Duration of OC usei,j, y     
<=1 54 29 (53.7%) REF REF 
>1-<=5 82 44 (53.7%) 0.88 (0.51-1.51) 0.99 (0.54-1.82) 
>5-<=10 56 31 (55.4%) 1.04 (0.59-1.85) 1.31 (0.69-2.46) 
>10 42 29 (69.0%) 1.58 (0.85-2.93) 1.87 (0.96-3.65) 
Ptrend   0.24 0.21 
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  Totala Fatal Casesb Model 1c Model 2d 
  n n (%) HR (95% CI) HR (95% CI) 
Hysterectomyk     
No 504 291 (57.7%) REF REF 
Yes 59 36 (61.0%) 0.78 (0.54-1.13) 0.82 (0.56-1.20) 
Total ovulatory yearsl     
≤27.5 104 65 (62.5%) REF REF 
>27.5-≤33.0 108 59 (54.6%) 0.77 (0.53-1.11) 0.82 (0.56-1.21) 
>33.0-≤36.5 140 66 (47.1%) 0.74 (0.52-1.07) 0.75 (0.52-1.10) 
>36.5 135 84 (62.2%) 0.96 (0.68-1.37) 1.07 (0.74-1.55) 
Ptrend     0.76 0.94 
 
Abbreviations: CI=confidence interval; FTP=full term pregnancy; HR=hazard ratio; m=months; OC=oral 
contraceptive; y=years. 
aTotal number of postmenopausal cases n=646. 
bTotal number of fatal cases n=422. 
cAdjusted for age at diagnosis (continuous) and stratified by study center. 
dAdjusted for age at diagnosis (continuous), year of diagnosis (continuous), BMI (<23kg/m2, ≥23-<25 
[reference], ≥25 -<30, ≥30), tumor stage (local [reference], regional, metastatic and unknown), smoking 
status (never [reference], former, current and unknown) and stratified by study center. 
eMissing for ≤2.5% of the cohort (postmenopausal women). 
fAmong parous women only. 
gBreastfeeding was missing for 7.3% of the cohort. 
hAmong parous women who had ever breastfed. 
iAmong OC users only. 
jDuration of OC use was missing for 8.6% of women. 
kHysterectomy was missing for 12.9% of the cohort. 




Supplemental Table 4. Characteristics of postmenopausal EOC cases stratified by ever versus never use of 
MHTa 








Age at diagnosis, y 65.9 (6.8) 62.7 (5.5) <0.0001b 
Duration OC usec, y 5.6 (6.2) 7.7 (7.2) 0.03b 
Number of FTPd,e 2.5 (1.2) 2.3 (0.9) 0.02b 
BMI, kg/m² 26.5 (4.6) 24.9 (4.0) <0.0001b 
Ever use OCs 31 56 <0.0001f 
Parous 83 86 0.41f 
Ever breastfede 84 81 0.38f 
Current smoker 19 19 0.89f 
Tumor site-not ovarian (FT, PPC) 7 9 0.50f 
Histology    
Serous 51 62 0.03f 
Mucinous 5 5  
Endometrioid 9 11  
Clear cell 5 3  
NOS  25 15  
Other 4 4  
Grade    
Grade well differentiated 4 5 0.76f 
Grade moderately differentiated 18 16  
Grade poorly/undifferentiated 30 30  
Grade unknown 48 49  
FIGO stage    
Stage I 15 9 0.07f 
Stage II 7 5  
Stage III 25 31  
Stage IV 12 10  
Unknown 41 45  
Stage    
Local 11 10 0.55f 
Regional 17 16  
Metastatic 56 64  
Unknown 16 10  
Abbreviations: FT=fallopian tube; FTP=full term pregnancy; OC=oral contraceptive; PPC=primary 
peritoneal cancer; y=years. 
aValues are means (SD) or percentages bChi-square test for trend (crude) cAmong ever OC users  dFTP 
defined as live or still births  eAmong parous women only  fChi-square test for heterogeneity (crude) 
